Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Abstract excerpt

In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochemical screening with high-throughput co-crystallography in the design of a series of compounds that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARalpha, PPARgamma, and PPARdelta. Transcriptional transactivation assays were used to select compounds from...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adipokines, Inflammation, and Metabolic Diseases
• Share to Adipose Tissue and Metabolism
• Share to Peroxisome Proliferator-Activated Receptors